GlassScriptPhysician profile
Mariela Riegger
NPI 1114561164
$3,060.85
in general payments reported to CMS, 2019-2025
31 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $386 · 2023: $746 · 2024: $943 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.23 | 2021-2025 | Sogroya, Norditropin, Wegovy |
| Abbvie INC. | $314.22 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $261.40 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $257.44 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $254.58 | 2023-2025 | Triptodur, Triptodur |
| Dexcom, INC. | $252.96 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Tolmar Pharmaceuticals, INC. | $148.21 | 2021-2022 | |
| Tolmar, INC. | $135.21 | 2023-2025 | Fensolvi |
| Neurocrine Biosciences, INC. | $88.09 | 2024-2025 | |
| Pfizer INC. | $85.34 | 2023-2025 | |
| Kyowa Kirin, INC. | $61.54 | 2023-2024 | Crysvita |
| Endo USA, INC. | $55.44 | 2024-2025 | Supprelin |
| Tandem Diabetes Care, INC. | $46.31 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Eton Pharmaceuticals, INC. | $44.78 | 2021 | |
| Insulet Corporation | $43.93 | 2021-2023 | Omnipod |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.24 | 2022-2023 | Lyumjev |
| Arbor Pharmaceuticals, INC. | $38.51 | 2022 | |
| Beta Bionics, INC. | $32.70 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sandoz INC. | $32.40 | 2025 | Omnitrope |
| Medtronic, INC. | $24.48 | 2021 | |
| Soleno Therapeutics, INC. | $23.95 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $23.83 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $23.51 | 2025 | Gvoke Hypopen |
| Embecta Corp. | $23.40 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $23.33 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.83 | 2022 | |
| Sobi, INC | $20.18 | 2022 | |
| Lifescan, INC. | $20.07 | 2021 | |
| Biomarin Pharmaceutical INC. | $20.02 | 2022 | |
| Zealand Pharma US, INC. | $18.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariela Riegger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.